Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhejiang Taimei Medical Technology Co., Ltd.
浙江太美醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2576)

VOLUNTARY ANNOUNCEMENT
PROPOSED REPURCHASE OF H SHARES PURSUANT TO THE GENERAL MANDATE TO REPURCHASE H SHARES

This announcement is made by Zhejiang Taimei Medical Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company (the "**Shareholders**") and potential investors with an update on the latest development of the Group.

Reference is made to the circular of the Company dated June 1, 2026 (the "**Circular**") in relation to, among other things, the proposed grant of a general mandate to the Board to repurchase the H Shares of the Company. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Shareholders of the Company granted the Board a general mandate to repurchase the H Shares of the Company (the "**H Share Repurchase Mandate**") at the AGM of the Company held on June 23, 2026. Pursuant to the H Share Repurchase Mandate, the Company may, from time to time, repurchase its H Shares on the open market of the Stock Exchange, subject to market conditions and the actual circumstances of the Company.

Pursuant to the H Share Repurchase Mandate, the Company is authorized to repurchase, during the relevant period, an aggregate number of H Shares not exceeding 10% of the total number of issued H Shares of the Company as at the date on which the H Share Repurchase Mandate was approved, excluding any treasury shares of the Company.

In repurchasing the H Shares, the Company intends to use funds from its internal resources, which may include surplus funds and retained profits, that are legally available for such purpose in accordance with the Articles of Association, the Listing Rules and the applicable PRC laws and regulations. Any premium payable on a repurchase may only be paid out of the profits of the Company before or at the time of the repurchase in the manner prescribed by PRC laws.

Pursuant to Rule 10.06(2) of the Listing Rules, the price at which the Company repurchases H Shares on any given occasion shall not be 5% or more above the average closing price of the H Shares for the five trading days immediately preceding such repurchase. Subject to the aforesaid restrictions, the Board has resolved that the repurchase price per H Share shall not exceed HK$11, and the Board will determine the specific repurchase price based on market conditions and the actual circumstances of the Company.

The H Share Repurchase Mandate shall remain valid from the date on which it was considered and approved at the AGM until the earlier of: (1) the conclusion of the next annual general meeting of the Company following the passing at the AGM of the resolution granting the H Share Repurchase Mandate; or (2) the date on which the authority conferred by the resolution granting the H Share Repurchase Mandate is revoked or varied by a special resolution at a general meeting of the Company.

The Board considers that, depending on the prevailing market conditions and funding arrangements, the repurchase of H Shares may enhance the net asset value per Share and/or earnings per Share, strengthen investors' confidence in the Company, help maintain the Company's reputation in the capital market and have a positive impact. Any such repurchase will only be made if the Board considers that it will benefit the Company and the Shareholders as a whole.

The Directors will exercise the powers of the Company to repurchase H Shares pursuant to the H Share Repurchase Mandate in accordance with the Listing Rules and the applicable PRC laws and regulations. No core connected person of the Company (as defined in the Listing Rules) has notified the Company that he/she has a present intention to sell any H Shares to the Company, or has undertaken not to sell any H Shares held by him/her to the Company. The Directors have no present intention to repurchase H Shares to such an extent as would give rise to an obligation under the Takeovers Code. The Directors do not propose to repurchase H Shares to such an extent that the public float would fall below 25%.

Shareholders and potential investors should note that any repurchase of H Shares will be subject to market conditions, the price of the Company's H Shares, funding arrangements and the Company's capital management needs, and will be made at the sole discretion of the Board. The Company gives no assurance as to the timing, number or price of any repurchase of H Shares, or that any repurchase of H Shares will be made. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Dr. ZHAO Lu
Chairman of the Board

Hong Kong, June 23, 2026

As at the date of this announcement, the Board comprises Dr. ZHAO Lu, Ms. WAN Yunyun, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming and Ms. NI Xiaomei as executive Directors, and Dr. JIANG Xiao, Mr. FUNG Che Wai Anthony and Dr. GONG Yan as independent non-executive Directors.